This Week in Health News: 11 Stories You Need to See
A roundup of the week's most newsworthy health industry press releases from PR Newswire, including updates on cannabis- and psilocybin-based treatments.
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.
The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.
New Survey Data Confirms Mental Health Remains Leading Challenge on College Campuses The survey confirms national reports that student mental health continues to decline. Furthermore, the survey also underscores campus leader concerns that institutions are not sufficiently prepared to offer students the necessary level of mental health support and resources.
Biden Administration Extends COVID-19 Public Health Emergency Funding The Emergency Declaration extension will enable state governments to access remaining emergency funds to prevent transmission of COVID-19 and other infectious particles by upgrading HVAC systems, deploying air purification units, and making health-focused investments in infrastructure overall.
Peloton Appoints Leslie Berland as Chief Marketing Officer Berland previously served as CMO at Twitter, where she oversaw marketing and communications, tasked with defining and deepening the brand's identity and influence globally. "Peloton is at a unique moment in its transformation journey, and I'm thrilled to be a part of it!" she said.
NAMUH and Ginkgo Bioworks Announce Partnership to Produce Multiple Infant Nutrition Products Through this partnership, NAMUH will leverage Ginkgo's expertise in yeast strain engineering and fermentation process development to enable the production of various HMOs through yeast fermentation and work to unlock the possibility of making infant formula nutritionally robust and much closer to human breast milk.
Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial This randomized, double-blind, placebo-controlled phase 2b study will evaluate the efficacy, safety and tolerability of APEX-52 microdose, orally administered synthetic psilocybin drug product in treating depression and anxiety among adults diagnosed with Post-Traumatic Stress Disorder (PTSD).
OncoK9 Liquid Biopsy Test Can Enhance Cancer Monitoring in Dogs, New Results Show Initially recommended for cancer screening and as an aid-in-diagnosis, OncoK9® ? The Liquid Biopsy Test for Dogstm is now also recommended for detection of residual disease and detection of recurrence in dogs previously diagnosed with cancer.
WellSet Launches First Holistic Self-Care Benefit Backed by Insurance WellSet provides unlimited access to thousands of live and on-demand classes spanning 20+ evidence-based practices designed to improve mind, body, and emotional health, like Acupressure, Self-Hypnosis, and EFT/Tapping, in addition to Yoga, Mindfulness, and more.
Helping Journalists Stay Up to Date on Industry News
These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.
Once they're signed up, reporters, bloggers and freelancers have access to the following free features:
Customization: Create a customized newsfeed that will deliver relevant news right to your inbox. Customize the newsfeed by keywords, industry, subject, geography, and more.
Photos and Videos: Thousands of multimedia assets are available to download and include with your next story.
Subject Matter Experts: Access ProfNet, a database of industry experts to connect with as sources or for quotes in your articles.
Related Resources: Read and subscribe to our journalist- and blogger-focused blog, Beyond Bylines, for media news roundups, writing tips, upcoming events, and more.
About PR Newswire and PR Newswire for Journalists
For more than 65 years, PR Newswire has been the industry leader with the largest, most comprehensive distribution network of print, radio, magazine, television stations, financial portals and trade publications. PR Newswire has an unparalleled global reach of more than 200,000 publications and 10,000 websites and is available in more than 170 countries and 40 languages.
PR Newswire for Journalists (PRNJ) is an exclusive community that includes over 20,000 journalists, bloggers and influencers who are logging into their PRNJ accounts specifically looking for story ideas. PR Newswire thoroughly researches and vets this community to verify their identity as a member of the press, blogger or influencer. PRNJ users cover more than 200 beats and verticals.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...